Sirtuin Pipeline

Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases, such as Type 2 Diabetes, and various forms of cancer, as well as mitochondrial, inflammatory, neurodegenerative and cardiovascular diseases.

Pipeline Highlights:

• SRT501, a formulation of resveratrol with roughly five times higher bioavailability than the chemical alone
• Two completed 28 day Phase 1b studies in Type 2 diabetes show safety, lowering fasting plasma glucose and insulin, and a significant lowering of glucose in an oral glucose tolerance test at the two hour time point.
• Completing a 3 month Phase 2a trial in patients with Type 2 diabetes who remain uncontrolled despite metformin therapy.
• Designated orphan drug status for resveratrol in the treatment of MELAS syndrome; ongoing Phase 1b trial MELAS
• Upcoming Phase 1b trial in oncology
• SRT2104, a new chemical entity (NCE) that activates SIRT1 - 1,000 times more potent than resveratrol
• Currently in a first-in-human Phase 1a trial to assess safety, tolerability, and pharmacokinetics